demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID-19 mild to moderate
COVID-19 mild to moderate
anti-interleukin-6
tocilizumab Capra

0 studies excluded by filtering options 2